New genetic test may predict colon cancer return

NCT ID NCT02110329

Completed Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a genetic test called QMPSF can help predict if stage II or III colon cancer will come back after surgery. Researchers analyzed tumor tissue from 401 patients for specific DNA changes. The goal was to see if these genetic markers are linked to cancer recurrence and survival rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this genetic test could help doctors better predict which colon cancer patients are at higher risk of recurrence, guiding more personalized treatment decisions.
What could go wrong: This is an observational study, not a treatment trial. The test is still experimental and may not prove accurate enough for routine use. Results need validation in larger, diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER STAGE II AND III

Contacts and locations

Locations

Chu Dijon

Dijon, 21079, France
Chu Hopitaux de Rouen

Rouen, 76031, France
Chu Lille

Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.